» Articles » PMID: 31146503

Lactate Dehydrogenases As Metabolic Links Between Tumor and Stroma in the Tumor Microenvironment

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2019 Jun 1
PMID 31146503
Citations 106
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is a metabolic disease in which abnormally proliferating cancer cells rewire metabolic pathways in the tumor microenvironment (TME). Molecular reprogramming in the TME helps cancer cells to fulfill elevated metabolic demands for bioenergetics and cellular biosynthesis. One of the ways through which cancer cell achieve this is by regulating the expression of metabolic enzymes. Lactate dehydrogenase (LDH) is the primary metabolic enzyme that converts pyruvate to lactate and vice versa. LDH also plays a significant role in regulating nutrient exchange between tumor and stroma. Thus, targeting human lactate dehydrogenase for treating advanced carcinomas may be of benefit. LDHA and LDHB, two isoenzymes of LDH, participate in tumor stroma metabolic interaction and exchange of metabolic fuel and thus could serve as potential anticancer drug targets. This article reviews recent research discussing the roles of lactate dehydrogenase in cancer metabolism. As molecular regulation of and in different cancer remains obscure, we also review signaling pathways regulating and expression. We highlight on the role of small molecule inhibitors in targeting LDH activity and we emphasize the development of safer and more effective LDH inhibitors. We trust that this review will also generate interest in designing combination therapies based on LDH inhibition, with being targeted in tumors and in stromal cells for better treatment outcome.

Citing Articles

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.

Cottrell T, Lotze M, Ali A, Bifulco C, Capitini C, Chow L J Immunother Cancer. 2025; 13(3).

PMID: 40054999 PMC: 11891540. DOI: 10.1136/jitc-2024-010928.


Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy.

Luo M, Wei H, Qiu M, Su C, Ning R, Zhou S Front Immunol. 2025; 16:1473962.

PMID: 40013138 PMC: 11861202. DOI: 10.3389/fimmu.2025.1473962.


Lactate metabolism in clonal plasma cells and its therapeutic implications in multiple myeloma patients with elevated serum LDH levels.

Chawla Y, Anderson E, Smith M, Jain S, Evans L, Neff J Cancer Metab. 2025; 13(1):9.

PMID: 39948621 PMC: 11827136. DOI: 10.1186/s40170-025-00379-1.


FOXO3a/miR-4259-driven LDHA expression as a key mechanism of gemcitabine sensitivity in pancreatic ductal adenocarcinoma.

Hsu T, Wang W, Chen H, Wang T, Su C, Liao P Cancer Metab. 2025; 13(1):7.

PMID: 39930542 PMC: 11809001. DOI: 10.1186/s40170-025-00377-3.


Plasma proteome fingerprint in kidney diseases.

Nikolsky K, Kopylov A, Nakhod V, Potoldykova N, Enikeev D, Butkova T Front Mol Biosci. 2025; 11:1494779.

PMID: 39896931 PMC: 11782039. DOI: 10.3389/fmolb.2024.1494779.


References
1.
Shelley M, Hartley L, FISH R, Groundwater P, Morgan J, Mort D . Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines. Cancer Lett. 1999; 135(2):171-80. DOI: 10.1016/s0304-3835(98)00302-4. View

2.
Bushunow P, Reidenberg M, Wasenko J, Winfield J, Lorenzo B, Lemke S . Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol. 1999; 43(1):79-86. DOI: 10.1023/a:1006267902186. View

3.
Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

4.
Vander Jagt D, Deck L, Royer R . Gossypol: prototype of inhibitors targeted to dinucleotide folds. Curr Med Chem. 2000; 7(4):479-98. DOI: 10.2174/0929867003375119. View

5.
Lewis B, Prescott J, Campbell S, Shim H, Orlowski R, Dang C . Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res. 2000; 60(21):6178-83. View